GlassScriptPhysician profile
Sharon K Brown
NPI 1770674467
$2,001.09
in general payments reported to CMS, 2019-2025
25 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $716 · 2022: $564 · 2023: $416 · 2024: $91.53 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $720.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $838.92 | 2021-2025 | |
| Hologic Sales and Service, LLC | $146.45 | 2023-2025 | Novasure, Myosure Tissue Removal Device, Acessa Provu System |
| Takeda Pharmaceuticals U.S.A., INC. | $130.08 | 2021-2022 | |
| Astellas Pharma US INC | $107.11 | 2021-2025 | Veozah, Myrbetriq |
| Amgen INC. | $90.80 | 2021-2022 | |
| Daiichi Sankyo INC. | $89.44 | 2021-2022 | |
| Myovant Sciences INC. | $78.87 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $68.76 | 2021 | |
| Pfizer INC. | $51.23 | 2021-2024 | |
| Novo Nordisk INC | $45.15 | 2022-2025 | Ozempic, Rybelsus |
| Evofem Biosciences, INC. | $38.85 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $36.94 | 2023-2025 | |
| Organon LLC | $36.15 | 2022-2023 | Jada System |
| Sumitomo Pharma America, INC. | $34.38 | 2023 | Myfembree |
| Shield Therapeutics INC | $31.19 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $30.21 | 2023 | Surgiflo Hemostatic Matrix |
| Avion Pharmaceuticals | $28.98 | 2021 | |
| Dexcom, INC. | $16.22 | 2025 | Dexcom G6 Transmitter |
| Eisai INC. | $15.69 | 2021 | |
| Exeltis, USA INC. | $15.61 | 2022 | |
| Boston Scientific Corporation | $15.27 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.45 | 2022 | |
| Sage Therapeutics, LLC | $14.37 | 2025 | Zurzuvae |
| Scynexis, INC. | $13.78 | 2022 | |
| Smith+Nephew, INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.